1. Orbital and chorioretinal manifestations of Erdheim-Chester disease treated with vemurafenib
- Author
-
Ryanne A. Brown, Andrea L. Kossler, Dita Gratzinger, Ruwan A. Silva, Laura C. Huang, Katie L. Topping, and Beth A. Martin
- Subjects
Chorioretinal ,medicine.medical_specialty ,Lipogranulomatous ,genetic structures ,Genetic enhancement ,Disease ,BRAF ,Orbital ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,lcsh:Ophthalmology ,Case report ,medicine ,Vemurafenib ,Histiocyte ,Genetic testing ,medicine.diagnostic_test ,business.industry ,medicine.disease ,Dermatology ,eye diseases ,Ophthalmology ,Histiocytosis ,lcsh:RE1-994 ,030220 oncology & carcinogenesis ,Erdheim–Chester disease ,030221 ophthalmology & optometry ,Xanthomatous ,business ,medicine.drug - Abstract
Purpose: We report a patient with severe multi-organ dysfunction of unknown origin who presented with bilateral orbital and chorioretinal manifestations that led to the diagnosis of Erdheim-Chester Disease (ECD). Observations: ECD is a rare, histiocytic, proliferative disorder characterized by multi-systemic organ involvement that has historically lacked effective therapy. Our patient underwent genetic testing that was positive for the BRAF V600E mutation; therefore, the patient was treated with vemurafenib. Conclusions and importance: This case demonstrates the rare orbital and intraocular manifestations of ECD and the unfortunate impact of a delayed diagnosis, the importance of early gene therapy testing for management decisions, and the utilization of targeted directed therapy to improve visual outcomes and quality of life. Keywords: Histiocytosis, Vemurafenib, Orbital, Chorioretinal, Xanthomatous, Lipogranulomatous, BRAF
- Published
- 2018